Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%)
Form 8-K Product Sales Detail by Product and Geographic Region
Latest, FY2023
-22.0%
Period ended Dec 31, 2023
Change on a year earlier
-53.0 pts
31.0% in FY2022
History
4 years
Since FY2020
Sources
4
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -22.0% | -53.0 pts | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 31.0% | +47.0 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | -16.0% | -40.0 pts | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 24.0% | – | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
Cite this data
StockData. (2026). Amgen Aimovig (erenumab-aooe — Migraine Prevention, legacy standalone disclosure) — Worldwide reported sales growth YoY (%) (%), annual FY2020–FY2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_aimovig_yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.